Adenine Nucleotide Analogues Locked in a Northern Methanocarba Conformation:  Enhanced Stability and Potency as P2Y 1 Receptor Agonists by Ravi, R. Gnana et al.
Adenine Nucleotide Analogues Locked in a Northern 
Methanocarba Conformation: Enhanced Stability and Potency as 
P2Y1 Receptor Agonists
R. Gnana Ravi†, Hak Sung Kim†, Jörg Servos‡, Herbert Zimmermann‡, Kyeong Lee†, Savitri 
Maddileti§, José L. Boyer§, T. Kendall Harden§, and Kenneth A. Jacobson*,†
Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of 
Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Building 8A, Room 
B1A-17, Bethesda, Maryland 20892-0810, Department of Pharmacology, University of North 
Carolina, School of Medicine, Chapel Hill, North Carolina 27599-7365, and AK Neurochemie, 
Biozentrum der J. W. Goethe-Universität, Marie-Curie-Strasse 9, D- 60439 Frankfurt am Main, 
Germany
Abstract
Preference for the Northern (N) ring conformation of the ribose moiety of nucleotide 5′-
triphosphate agonists at P2Y1, P2Y2, P2Y4, and P2Y11 receptors, but not P2Y6 receptors, was 
established using a ring-constrained methanocarba (a 3.1.0-bicyclohexane) ring as a ribose 
substitute (Kim et al. J. Med. Chem. 2002, 45, 208–218.). We have now combined the ring-
constrained (N)-methanocarba modification of adenine nucleotides with other functionalities 
known to enhance potency at P2 receptors. The potency of the newly synthesized analogues was 
determined in the stimulation of phospholipase C through activation of turkey erythrocyte P2Y1 or 
human P2Y1 and P2Y2 receptors stably expressed in astrocytoma cells. An (N)-methanocarba-2-
methylthio-ADP analogue displayed an EC50 at the hP2Y1 receptor of 0.40 nM and was 55-fold 
more potent than the corresponding triphosphate and 16-fold more potent than the riboside 5′-
diphosphate. 2-Cl–(N)-methanocarba-ATP and its N6-Me analogue were also highly selective, full 
agonists at P2Y1 receptors. The (N)-methanocarba-2-methylthio and 2-chloromonophosphate 
analogues were full agonists exhibiting micromolar potency at P2Y1 receptors, while the 
corresponding ribosides were inactive. Although β,γ-methylene-ATP was inactive at P2Y 
receptors, β,γ-methylene-(N)-methanocarba-ATP was a potent hP2Y1 receptor agonist with an 
EC50 of 160 nM and was selective versus hP2Y2 and hP2Y4 receptors. The rates of hydrolysis of 
Northern (N) and Southern (S) methanocarba analogues of AMP by rat 5′-ectonucleotidase were 
negligible. The rates of hydrolysis of the corresponding triphosphates by recombinant rat 
NTPDase1 and 2 were studied. Both isomers were hydrolyzed by NTPDase 1 at about half the rate 
of ATP hydrolysis. The (N) isomer was hardly hydrolyzed by NTPDase 2, while the (S) isomer 
was hydrolyzed at one-third of the rate of ATP hydrolysis. This suggests that new, more stable and 
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selective nucleotide agonists may be designed on the basis of the (N)-conformation, which greatly 
enhanced potency at P2Y1 receptors.
 Introduction
The P2 nucleotide receptors consist of two families: G-protein-coupled receptors (GPCR) 
termed P2Y, of which seven mammalian subtypes (P2Y1,2,4,6,11,12,13) have been cloned, and 
ligand-gated cation channels termed P2X, of which seven mammalian subtypes (P2X1–7) 
have been cloned.1–3 Adenine nucleotides are required for activation of P2Y1, P2Y11, 
P2Y12, and P2Y13 subtypes, while uracil nucleotides activate P2Y2, P2Y4, and P2Y6 
subtypes. P2Y receptors may couple to multiple second messengers, but all except the 
recently cloned3–5 P2Y12 and P2Y13 receptors lead to activation of phospholipase C (PLC) 
via Gq, resulting in a rise in intracellular calcium. The Gi-coupled P2Y12 and P2Y13 
receptors occur on a more distant branch of the sequence dendrogram than the other 
members of the P2Y family6 and are closer in sequence to a newly characterized GPCR that 
is selective for sugar nucleotides (e.g. UDP-glucose).7
The medicinal chemistry of P2 receptors is underdeveloped compared to many other 
GPCRs.8–10 Reasons for the lack of progress in this field include nonselectivity, chemical 
instability, heterogeneity, and nonbioavailability of known ligands. Other difficulties in 
characterizing the receptors include the enzymatic instability of the phosphate groups of 
nucleotides to form biologically active metabolites. Indeed, most of the known P2 
antagonists also inhibit ectonucleotidase activity, thus augmenting the effects of the 
endogenous agonist(s). Receptor heterogeneity,11 oligomerization,12 and desensitization13 
are further complications.
Despite the above-mentioned difficulties, the SAR of ATP analogues (e.g., 1–5; Chart 1) at 
P2 receptors has been probed.8–10 Selective agonists (P2Y1, P2Y6)14,15 and antagonists 
(P2Y1, P2Y12, P2X1, P2X7)14,16–19 have been reported for only a few of the subtypes. 2-
Methylthio-ATP (1, 2-MeSATP) is one of the most potent agonists at a number of P2Y and 
P2X receptors.10 It was formerly regarded as selective for P2Y receptors; however, by 
adjustment for its lability in classical smooth muscle assays in which P2X receptors have 
been assayed, it is a highly potent agonist within the P2X superfamily.20 At the P2Y1 
receptor, which is present in the heart, skeletal and various smooth muscles, prostate, ovary, 
and brain,21 the potency order for activation is 2-methylthioadenosine 5′-diphosphate (2-
MeSADP) > 2-Me-SATP > ADP > ATP, and AMP and UTP are inactive. 2-Chloro-ATP and 
N6-methyl-ATP (2 and 3, respectively) are moderately potent agonists at P2Y1 receptors.22 
MRS 2055 4 (N6-methyl-2-(5-hexenyl)thioadenosine 5′-triphosphate) is an agonist with 
micromolar potency at a glial adenylate cyclase coupled P2Y receptor (now identified as 
identical to P2Y12)23,24 but is inactive at P2Y1 receptors. β,γ-Methylene ATP 5 activates 
P2X1, but not P2Y1, receptors.21,22
P2Y receptor ligands are being explored for therapeutic applications in the cardiovascular, 
endocrine, and other systems. A selective P2Y1 receptor agonist may have potential as an 
antihypertensive or antidiabetic agent.25–27 A selective antagonist of the P2Y1 receptor may 
be potentially useful in antithrombotic therapy,28,29 since activation of this subtype is 
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associated with the initial shape change during platelet aggregation.29 ATP analogues have 
been shown to be effective insulin secretagogues.30 A P2Y1 receptor in osteoclasts has been 
linked to bone disintegration.31 First cloned from chick brain,32 the distribution of the P2Y1 
receptor in the human brain has been described33 and abnormalities in P2Y1 receptor levels 
have been detected in the Alzheimer’s brain.34 A linkage between P2Y1 receptors and the 
MAP kinase/apoptosis pathway has been proposed.35 Selective agonists and antagonists at 
the P2Y1 receptor have been reported.10,14
3′,5′-Bisphosphate nucleotides have been explored as selective antagonists of the P2Y1 
receptor, and nearly nanomolar affinities have been achieved.14 The ribose moiety of P2Y1 
receptor antagonists may be replaced with carbocylics, smaller and larger rings, acyclics, 
and conformationally constrained rings,14 resulting in retention of affinity for the receptor. 
The ribose rings of nucleosides and nucleotides can adopt a range of conformations, 
although their target receptors likely prefer specific conformations. For P2Y1 antagonists we 
have replaced the ribose moiety with a carbocyclic ring locked in a preferred conformation, 
a fusion of cyclopropane and cyclopentane rings known as the methanocarba 
modification.36–38 Two structural variations, depending on the position of the cyclopropane 
ring, restrict the ring pucker, i.e., hold the ribose-like ring (pseudosugar) in either a Northern 
(N, 2′-exo) 6a or Southern (S, 2′-endo) 6c envelope conformation (Chart 1), as defined in the 
pseudorotational cycle. Preference for the Northern (N) ring conformation of the ribose 
moiety of nucleoside 5′-triphosphate agonists at P2Y1, P2Y2, P2Y4, and P2Y11 receptors, 
but not P2Y6 receptors, was established using a constrained methanocarba (bicyclic) ring.39
In the present study we combined the ring-constrained (N)-methanocarba modification of 
adenine nucleotides with other functionalities known to enhance potency at P2 receptors. In 
several cases, the constrained ring conferred dramatic increases in agonist potencies at P2Y1 
receptors, and generally the modification preserved the potencies at P2Y2 receptors.
 Results
 Chemical Synthesis
We prepared methanocarbocyclic analogues of various synthetic adenine nucleotides (Table 
1) in which fused cyclopropane and cyclopentane rings fixed the pseudoribose moiety in a 
rigid (N)-envelope conformation. The unsubstituted ATP 6a and AMP 7a analogues were 
reported in a previous study.39 The new nucleotide analogues 8a–15a and 17a were prepared 
in the ammonium salt form according to the methods shown in Schemes 1 and 2 and were 
tested biologically as agonists at various P2Y receptors (Table 1). Identity was confirmed 
using NMR (1H and 31P) and high-resolution mass spectrometry, and purity was 
demonstrated using high-pressure liquid chromatography (HPLC) in two different solvent 
systems (Table 2).
As in the previous study,39 since the phosphorus oxychloride method40,41 was unsatisfactory 
for phosphorylation of (N)-methanocarba nucleosides at the 5′-hydroxyl group, an 
alternative multistep process was used. This consisted of the formation of a monophosphate 
using the phosphoramidite method followed by condensation with additional phosphate or 
pyrophosphate groups using carbonyldiimidazole. By this method, the monophosphate 
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analogues were cleanly converted to either di- or triphosphate via a phosphorimidazolidate 
intermediate.41 During the sequence, it was necessary to hydrolyze the cyclic carbonates42 
38–41, which were formed at the 2′,3′-dihydroxy groups, using a 5% triethylamine solution.
The (N)-methanocarba analogues of various ATP derivatives substituted at the 2- and/or 6-
positions of the purine base moiety or at the β,γ position of the triphosphate moiety were 
prepared by this approach. To construct the pseudoribose ring leading to the (N)-
methanocarbaadenosine precursors, a 3.1.0-bicyclohex-ane structure was prepared by the 
general approach of Lee et al.,43 which utilized ring closure metathesis. An adenine 
precursor 18 or 19 was condensed with the protected bicycloheptane derivative 2043 using 
Mitsunobu conditions to give 2139 or 22 (Scheme 1). To introduce an amino or methylamino 
group at the 6-position, it was necessary to substitute 6-Cl with the corresponding amine 
following the Mitsunobu reaction to yield 23–26. Deprotection of the 5′-benzyl group of 23–
26 was carried out smoothly using Pd black/formic acid, even in the presence of 2-chloro 
substitution, to give 27, 29, and 30. This was followed by 5′-phosphorylation using a 
phosphoramidite method44 to give the di-tert-butyl protected monophosphates 31, 34, and 
35. Alternatively, the 2-chloro group of 27 was replaced with methylthio to give the 
nucleoside 28, leading to the protected monophosphate 32. In the process of synthesis of the 
2-methylthio-AMP derivative 32, the corresponding sulfoxide 33 was isolated as a 
byproduct. The monophosphates 31–35 were deprotected and either tested biologically or 
carried further to the di- and triphosphates by the method shown in Scheme 1. The (N)-
methanocarba β,γ-methylene triphosphate analogue 17a was prepared from the unsubstituted 
AMP equivalent 7a39 using methylene diphosphonate instead of pyrophosphate (Scheme 2).
Three riboside 5′-monophosphates 10b, 11b, and 13b were prepared using methods shown 
in Scheme 3 for comparison to the corresponding (N)-methanocarba derivatives. The 
isopropylidene group was used as protection for the 2′- and 3′-hydroxyl groups, and 
phosphorylation was carried out using the phosphoramidite method, as above.
 Biological Activity
(N)-Methanocarba analogues (denoted “a”, Table 1) were tested for agonist activity by 
measuring P2Y1-receptor-promoted phospholipase C activity in turkey erythrocyte 
membranes and by measuring inositol phosphate accumulation in 1321N1 human 
astrocytoma cells stably expressing the human P2Y1, P2Y2, P2Y4, or P2Y11 receptors. In 
each case, full concentration effect curves were generated and EC50 values from at least 
three separate experiments were determined. The agonist potencies of the corresponding 
ribose-containing nucleotides (denoted “b”) were simultaneously determined for comparison 
purposes.
Given the high potencies observed with (N)-methanocarba analogues of ATP and UTP and 
the much greater potency of the (N)-methanocarba as opposed to (S)-methanocarba 
conformation, we extended our studies to (N)-methanocarba derivatives synthesized 
containing various functionalities that we and others have shown to produce potent or 
receptor-selective adenine nucleotide analogues.8–10 As has been observed for adenine 
nucleotides, substitution at the 2-position, such as 2-methylthio, in the (N)-methanocarba-
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nucleotide series enhanced P2Y1 receptor potency. Thus, the high P2Y1 potency of 2-
MeSATP 8b (Figure 1) was preserved in the corresponding (N)-methanocarba analogue 8a. 
The most potent P2Y1 agonist in this series was the 2-methylthio diphosphate analogue 9a 
(Figure 2), which displayed an EC50 of 0.88 nM at the turkey P2Y1 receptor and was 7-fold 
more potent than the corresponding ribose analogue 9b and 26-fold more potent than 8a. At 
other receptors 9a was inactive (P2Y4, P2Y11) or weakly active (P2Y2). The (N)-
methanocarba-2-methylthio monophosphate analogue 10a and the (N)-methanocarba-2-
chloro monophosphate analogue 13a were full agonists exhibiting micromolar potency at the 
turkey and human P2Y1 receptors. Oxidation of the thioether to a sulfoxide, in 11a, reduced 
tP2Y1 receptor potency by 30-fold. The corresponding 5′-monophosphate ribosides 10b, 
11b, and 13b were inactive at P2Y1 receptors. The (N)-methanocarba-2-chloro 5′-
triphosphate analogue 12a was 240-fold more potent at the turkey P2Y1 receptor than the 
corresponding riboside 12b.
As for the riboside series, substitution at the exocyclic amine of adenine was tolerated for 
(N)-methanocarba analogues acting as P2Y receptor agonists. The N6-methyl 5′-
triphosphate analogue 14a was a potent agonist at the turkey and human P2Y1 receptors and 
was 5-fold more potent as a full agonist at the hP2Y1 than at the hP2Y2 receptor. 
Combination of N6-methyl and 2-chloro modifications in 15a resulted in a very potent 
agonist for the turkey and human P2Y1 receptors and selectivity for the hP2Y1 receptor 
versus hP2Y2 receptor of 930-fold. None of the (N)-methanocarba analogues of adenine 
nucleotide derivatives studied here were agonists at the human P2Y4 receptor (data not 
shown).
Since the 2-chloro-N6-methyl 5′-triphosphate analogue 15a was a potent P2Y1 receptor 
agonist, compound 16a45 was designed to evaluate the feasibility of replacing the 
triphosphate moiety with an uncharged moiety. However, it was inactive either as an agonist 
or as an antagonist at the turkey P2Y1 receptor. β;,γ-Me-ATP 17b was inactive as an agonist 
at the P2Y1 receptor.46,47 In contrast, and consistent with the potency enhancement 
observed for other nucleotide analogues, the (N)-methanocarba-β,γ-methylene analogue 17a 
was a relatively potent (EC50 = 11 μM) full agonist at the turkey P2Y1 receptor and a very 
potent (EC50 = 160 nM) agonist at the hP2Y1 receptor (Figure 3). In contrast, this analogue 
was inactive at the P2Y2 and P2Y4 receptors.
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Because of the well-established lability of nucleotide analogues in pharmacological studies, 
the enzymatic stability of the simple (N)-methanocarba and (S)-methanocarba analogues of 
AMP and ATP was investigated (Tables 3 and 4). Neither the (N)-methanocarba nor (S)-
methanocarba 5′-monophosphate derivatives 7a and 7c, respectively, were substrates for 
recombinant rat ecto- 5′-nucleotidase (Table 3).48 Hydrolysis of the (N)-methanocarba and 
(S)-methanocarba derivatives of ATP 6a and 6c, respectively, by recombinant rat 
ectoapyrase (NTPDase1) and ecto-ATPase (NTPDase2)49 stably expressed in CHO cells was 
also examined (Table 4). The (N)-methanocarba-ATP analogue was resistant to hydrolysis 
by NTPDase2 (4% as effective as ATP as a substrate), whereas the corresponding (S)-
methanocarba-ATP was hydrolyzed by NTPDase2 at one-third (34%) the rate of ATP 
hydrolysis. In contrast, both molecules were good substrates for NTPDase1, at about half the 
rate of ATP hydrolysis (52% and 57%, respectively).
 Discussion
In the previous study,39 we concluded that substitution of the ribose moiety with fused 
cyclopentane and cyclopropane rings in a pseudorotational (N)-conformation produced 
agonists at certain adenine and uracil nucleotide activated P2Y receptors. At P2Y1, P2Y2, 
P2Y4, and P2Y11 receptors, but not P2Y6 receptors, an (N)-methanocarba analogue was 
much more potent than the corresponding molecule constrained in the Southern 
conformation. Here, we have extended the synthesis to multiple substituted analogues of 
ring-constrained (N)-methanocarba-ATP, ADP, and AMP and illustrated that these 
derivatives exhibit as high or even higher potency for activation than the corresponding 
riboside, depending on the P2Y subtype involved. In some cases, alreadypotent ATP 
analogues were increased in potency upon (N)-methanocarba modification. In other cases, 
an inactive compound became biologically active upon such substitution.
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A key finding in this study is that remarkably potent agonists, especially at the P2Y1 
receptor, can be produced by introducing the (N)-methanocarba modification into molecules 
having other substitutions known to increase P2Y receptor potency. This was very notable in 
the (N)-methanocarba analogues of 2-Cl-ATP 13a and N6-Me-ATP 14a, which exhibited 
increases in potency in the (N)-methanocarba form versus ribosides of >200-fold. However, 
perhaps the most remarkable enhancement of activity occurred with β,γ-Me-ATP, although a 
full agonist at P2X receptors is not an agonist (or antagonist) at the P2Y1 and other P2Y 
receptors. However, the (N)-methanocarba analogue of β,γ-Me-ATP was a full agonist at the 
turkey and human P2Y1 receptors, exhibiting an EC50 for the human receptor of 160 nM. 
We have not yet extended this analysis to a direct comparison of relative activities of (N)- 
versus (S)-conformers to molecules that also possess other functional groups, e.g., 2-MeS or 
N6-CH3 substitution, known to increase binding affinity and selectivity for P2Y receptor 
agonists.
As we have observed with many different molecules that were synthesized and tested 
previously, results in human and turkey P2Y1 receptors were similar. The potencies 
determined in assays of phospholipase C in turkey erythrocyte membranes corresponded 
closely to the EC50 values determined for the same molecules at the recombinant human 
P2Y1 receptor stably expressed in 1321N1 human astrocytoma cells. This correlation was 
closest with a series of analogues containing the (N)-methanocarba substitution with various 
functional groups, e.g., 2-Cl, 2-MeS, N6-CH3, that we and others had previously 
demonstrated to increase P2Y receptor agonist potency in the riboside series. An explanation 
for the relatively large difference in apparent potency of the (N)-methanocarba analogue of 
β,γ-Me-ATP at the turkey versus human P2Y1 receptor is not readily apparent.
Although not studied in detail here, the (N)-methanocarba analogues exhibit resistance to 
hydrolysis relative to naturally occurring nucleotides. This observation may be particularly 
significant for 5′-monophosphate derivatives, since we have shown that they potently and 
selectively activate P2Y1 receptors but may be some-what stable to dephosphorylation by 5′-
nucleotidase. However, it should be pointed out that this resistance to hydrolysis would at 
most only make a minor contribution to the very large difference in potencies seen between 
certain (N)-methanocarba compounds and their natural ribose counterpart. That is, the Km/
Vmax values of ecto-nucleotidases on 1321N1 cells do not result in sufficient nucleotide 
hydrolysis to result in large shifts in the activation curves of, for example, ATP or UTP. 
More work will be required to obtain a clearer view on the capacity of the (N)-methanocarba 
molecules to serve as substrates for nucleotide-metabolizing ectoenzymes.
Thus, we established that constraining the ribose-like ring as methanocarba analogues was 
an important principle for producing P2Y receptor-subtype selectivity, similar to our 
previous demonstration of this phenomenon for P2Y1 receptor antagonists. The (N)-
methanocarba analogues generally displayed increased potency over the corresponding 
nucleotide agonists at the P2Y1 and P2Y2 receptors. The high potency of several of the 
derivatives (e.g., the selective P2Y1 receptor agonist 9a) suggested the possibility of 
preparation of high-affinity radioligands in the (N)-methanocarba series. The potent and 
selective P2Y1 agonists (EC50 in nM at the tP2Y1 receptor unless otherwise noted) found in 
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the present study were the following: 9a (0.88), 12a (3), 15a (9), 8a (23), 17a (160 at 
human), and 10a (590). Compound 14a was roughly equipotent at P2Y1 and P2Y2 receptors.
In conclusion, remarkable P2Y1 potency was generated in derivatives that combined the (N)-
methanocarba modification with other functional groups known to enhance potency and/or 
selectivity in P2 receptor agonists. These molecules provide a new armamentarium for the 
study of P2Y receptors. Moreover, they provide an attractive new chemical backbone on 
which to build highly potent and selective P2Y receptor agonists and antagonists that, in 
lacking a ribose moiety, are not nucleotides, and therefore, they are less likely to bind to the 
myriad of nucleotide binding proteins that are not P2Y receptors. Furthermore, enhanced 
stability to some nucleotidase enzymes is indicated in the methanocarba series. These 
findings promise to be useful for defining the microscopic determinants of the binding sites 
on these receptors and for designing novel pharmacological probes and/or therapeutic 
agents.
 Experimental Section
 1. Chemical Synthesis
 —Nucleosides and synthetic reagents were purchased from Sigma Chemical Co. (St. 
Louis, MO) and Aldrich (Milwaukee, WI). 2,6-Dichloropurine was obtained from Sigma. 
The protected intermediate 21 was synthesized in our laboratory as described.43,45 (N)-
Methanocarba analogues of ATP 6a and AMP 7a and the corresponding (±)-(S)-
methanocarba analogues 6c and 7c, respectively, were prepared as described.39 Compound 
16a was prepared as described.45
1H NMR spectra were obtained with a Varian Gemini-300 spectrometer (300 MHz) using 
D2O/CDCl3 and CD3OD as a solvent. 31P NMR spectra were recorded at room temperature 
by use of a Varian XL-300 spectrometer (121.42 MHz); orthophosphoric acid (85%) was 
used as an external standard.
Purity of compounds was checked using a Hewlett-Packard 1090 HPLC apparatus equipped 
with an SMT OD-5-60 RP-C18 analytical column (250 mm × 4.6 mm; Separation Methods 
Technologies, Inc., Newark, DE) in two solvent systems.
System A was a linear gradient solvent system consisting of 0.1 M TEAA/CH3CN from 
95/5 to 40/60 in 20 min, and the flow rate was 1 mL/min. System B was a linear gradient 
solvent system consisting of 5 mM TBAP/CH3CN from 80/20 to 40/60 in 20 min, and the 
flow rate was 1 mL/min. System C was a linear gradient solvent system consisting of 0.1 M 
TEAB/CH3CN from 100/0 to 90/10 in 20 min, and the flow rate was 1 mL/min.
Peaks were detected by UV absorption using a diode array detector. All derivatives tested for 
biological activity showed ≥97% purity in the HPLC systems.
Low-resolution CI(NH3) (chemical ionization) mass spectra were carried out with Finnigan 
4600 mass spectrometer, and high-resolution EI (electron impact) mass spectrometry was 
carried out with a VG7070F mass spectrometer at 6 kV. High-resolution FAB (fast-atom 
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bombardment) mass spectrometry was performed with a JEOL SX102 spectrometer using 6 
kV Xe atoms following desorption from a glycerol matrix.
Purification of the nucleotide analogues for biological testing was carried out on DEAE-A25 
Sephadex columns as described above.
 General Phosphorylation Procedure: Synthesis of (N)-Methanocarbaadenosine 
Derivatives (23–26). (1′S,2′ R,3′S,4′R,5′S)-4-(6-Amino-9H-purin-9-yl)-1-
[(phenylmethoxy)methyl]bicyclo[3.1.0]hexane-2,3-(O-isopropylidene) (23): To a solution 
of 21 (0.2 g, 0.47 mmol) in i-PrOH (3 mL) was added NH3 (2 M solution in i-PrOH, 5 mL, 
10 mmol), and the reaction mixture was heated at 90 °C in a closed tube for 15 h for 
complete reaction. The resulting mixture was concentrated under reduced pressure, and the 
residue obtained was purified by flash chromatography using 9/1 CHCl3/MeOH to furnish 
0.182 g of 23 (95%). 1H NMR (CDCl3) δ 8.35 (s, 1H), 8.30 (s, 1H), 7.37 (s, 5H), 5.87 (bs, 
2H), 5.31 (d, 1H, J = 6.8 Hz), 5.13 (s, 1H), 4.64 (qAB, 2H, J = 11.7, 20.5 Hz), 4.51 (d, 1H, J 
= 6.8 Hz), 3.97 (d, 1H, J = 10.7 Hz), 3.35 (d, 1H, J = 10.7 Hz), 1.72–1.62 (m, 1H), 1.55 (s, 
3H), 1.32–1.26 (m, 1H), 1.23 (s, 3H), 1.00–0.93 (m, 1H).
Compounds 24 and 25 were synthesized from 21, and 26 was synthesized from 22. All were 
produced in 90–95% yields.
 (1′S,2′R,3′S,4′R,5′S)-4-(6-Methylamino-9H-purin-9-yl)-1-
[(phenylmethoxy)methyl]bicyclo[3.1.0]hexane-2,3-(O-isopropylidene) (24): 1H NMR 
(CDCl3) δ 8.41 (s, 1H), 8.22 (s, 1H), 7.40–7.30 (m, 5H), 6.01 (bs, 1H), 5.30 (d, 1H, J = 7.2 
Hz), 5.12 (s, 1H), 4.62 (qAB 2H, J = 12.1, 20.9 Hz), 4.51 (d, 1H, J = 7.2 Hz), 3.94 (d, 1H, J 
= 9.9 Hz), 3.35 (d, 1H, J = 9.9 Hz), 3.21 (s, 3H), 1.70–1.62 (m, 1H), 1.55 (s, 3H), 1.29–1.25 
(m, 1H), 1.22 (s, 3H), 0.98–0.92 (m, 1H).
 (1′S,2′R,3′S,4′R,5′S)-4-(6-Amino-2-chloro-9H-purin-9-yl)-1-
[(phenylmethoxy)methyl]bicyclo[3.1.0]hexane-2,3-(O-isopropylidene) (25): 1H NMR 
(CDCl3) δ 8.22 (s, 1H), 7.40–7.33 (m, 5H), 6.48 (bs, 2H), 5.32 (d, 1H, J = 7.15 Hz), 5.07 (s, 
1H), 4.61 (qAB, 2H, J = 12.1, 19.2 Hz), 4.51 (d, 1H, J = 7.2 Hz), 3.94 (d, 1H, J = 9.9 Hz), 
3.42 (d, 1H, J = 9.9 Hz), 1.64–1.56 (m, 1H), 1.55 (s, 3H), 1.30–1.26 (m, 1H), 1.24 (s, 3H), 
0.98–0.933 (m, 1H).
 (1′S,2′R,3′S,4′R,5′S)-4-(6-Methylamino-2-chloro-9H-pu-rin-9-yl)-1-
[(phenylmethoxy)methyl]bicyclo[3.1.0]hexane-2,3-(O-isopropylidene) (26): 1H NMR 
(CDCl3) δ 8.15 (s, 1H), 7.40–7.28 (m, 5H), 6.29 (bs, 1H), 5.32 (d, 1H, J = 7.1 Hz), 5.05 (s, 
1H), 4.61 (qAB, 2H, J = 12.4, 17.6 Hz), 3.90 (d, 1H, J = 10.2 Hz), 3.42 (d, 1H, J = 10.2 Hz), 
3.17 (bs, 3H), 1.60–1.56 (m, 1H), 1.54 (s, 3H), 1.30–1.26 (m, 1H), 1.24 (s, 3H), 0.96–0.92 
(m, 1H).
 Procedure for Debenzylation of 24–26: See ref 39.
 (1′S,2′R,3′S,4′R,5′S)-4-(6-Amino-2-chloro-9H-purin-9-yl)-1-
[hydroxymethyl]bicyclo[3.1.0]hexane-2,3-(O-isopropylidene) (27): 1H NMR (CDCl3) δ 
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7.90 (s, 1H), 5.56 (d, 1H, J = 7.4 Hz), 4.79 (s, 1H), 4.66 (d, 1H, J = 7.4 Hz), 4.26 (d, 1H, J = 
11.5 Hz), 3.37 (d, 1H, J = 11.5 Hz), 1.78–1.70 (m, 1H), 1.55 (s, 3H), 1.26 (s, 3H), 1.20–1.14 
(m, 1H), 1.20–0.96 (m, 1H).
 (1′S,2′R,3′S,4′R,5′S)-4-(6-Methylamino-9H-purin-9-yl)-1-
[hydroxymethyl]bicyclo[3.1.0]hexane-2,3-(O-isopropylidene) (29): 1H NMR (CDCl3) δ 
8.36 (s, 1H), 7.77 (s, 1H), 5.61 (d, 1H, J = 7.4 Hz), 4.78 (s, 1H), 4.65 (d, 1H, J = 7.4 Hz), 
4.33 (d, 1H, J = 11.5 Hz), 3.25 (d, 1H, J = 11.5 Hz), 3.20 (bs, 3H), 1.79–1.74 (m, 1H), 1.55 
(s, 3H), 1.25 (s, 3H), 1.17–1.13 (m, 1H), 1.01–0.96 (m, 1H).
 (1′S,2′R,3′S,4′R,5′S)-4-(6-Methylamino-2-chloro-9H-pu-rin-9-yl)-1-
[hydroxymethyl]bicyclo[3.1.0]hexane-2,3-(O-isopropylidene) (30): 1H NMR (CD3OD) δ 
8.14 (s, 1H), 5.30 (d, 1H, J = 7.1 Hz), 4.87 (s, 1H), 4.61 (d, 1H, J = 7.1 Hz), 3.91 (d, 1H, J = 
11.5 Hz), 3.52 (d, 1H, J = 11.5 Hz), 3.00 (bs, 3H), 1.64–1.60 (m, 1H), 1.44 (s, 3H), 1.18 (s, 
3H), 1.08–1.04 (m, 1H), 0.92–0.87 (m, 1H).
 (1′S,2′R,3′S,4′R,5′S)-4-(6-Amino-2-methylthio-9H-purin-9-yl)-1-
[hydroxymethyl]bicyclo[3.1.0]hexane-2,3-(O-isopropylidene) (28): Compound 27 (30 
mg, 0.086 mmol) was dissolved in DMF (1.5 mL) and treated with sodium thiomethoxide 
(90 mg, 1.3 mmol). The reaction mixture was heated in a sealed tube at 90 °C for 1.5 h. The 
solvent was removed under vacuum, and the product was purified by preparative thin-layer 
chromatography (9/1 CHCl3/MeOH) to furnish 25 mg of 28 (80%). 1H NMR (CDCl3) δ 
7.76 (s, 1H), 5.82 (bs, 2H), 5.56 (d, 1H, J = 7.1 Hz), 4.78 (s, 1H), 4.71 (d, 1H, J = 7.1 Hz), 
4.25 (d, 1H, J = 11.5 Hz), 3.35 (d, 1H, J = 11.5 Hz), 2.59 (s, 3H), 1.71–1.66 (m, 1H), 1.55 (s, 
3H), 1.26 (s, 3H), 1.18–1.14 (m, 1H), 0.99–0.93 (m, 1H).
 Protected (N)-Methanocarbaadenosine 5′-Monophosphate Derivatives (31–35): 
These monophosphate derivatives were synthesized by procedures similar to those used to 
prepare the unsubstituted adenine analogue.39
 (1′S,2′R,3′S,4′R,5′S)-4-(6-Amino-2-chloro-9H-purin-9-yl)-1-[(di-tert-butyl 
phosphate)methyl]bicyclo[3.1.0]hex-ane-2,3-(O-isopropylidene) (31): 1H NMR (CDCl3) 
δ 8.23 (s, 1H), 6.91 (bs, 2H), 5.41 (d, 1H, J = 7.1 Hz), 5.16 (s, 1H), 4.64 (d, 1H, J = 7.1 Hz), 
4.59 (dd, 1H, J = 5.5, 11.0 Hz), 3.98 (dd, 1H, J = 6.3, 11.0 Hz), 1.84–1.76 (m, 1H), 1.63 (s, 




phosphate)methyl]bicyclo[3.1.0]hexane-2,3-(O-isopropylidene) (33): To a mixture of 28 
(20 mg, 0.055 mmol) and tetrazole (0.012 g, 0.165 mmol) in anhydrous THF (2 mL) was 
added di-tert-butyl-N,N-diethylphosphoramidite (0.023 mL, 0.083 mmol), and the mixture 
was stirred at room temperature overnight. The reaction mixture was cooled to −78 °C, and a 
solution of 70% mCPBA (0.012 g, 0.066 mmol) in 1 mL of CH2Cl2 was warmed to room 
temperature. A total of 1 mL MeOH was added, and the mixture was concentrated and 
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purified by preparative TLC using 10% MeOH in CHCl3 to furnish 32 (12 mg) and 33 (12 
mg).
32: 1H NMR (CDCl3) δ 7.98 (s, 1H), 5.87 (bs, 2H), 5.31 (d, 1H, J = 7.2 Hz), 5.07 (s, 1H), 
4.59 (d, 1H, J = 7.2 Hz), 4.49 (dd, 1H, J = 5.8, 11.0 Hz), 3.83 (dd, 1H, J = 6.3, 11.0 Hz), 
2.59 (s, 3H), 1.75–1.70 (m, 1H), 1.55 (s, 3H), 1.49 (s, 18H), 1.30–1.27 (m, 1H), 1.23 (s, 3H), 
1.05–1.00 (m, 1H).
33: 1H NMR (CDCl3) δ 8.26 (s, 1H), 6.66 (bs, 2H), 5.33 (d, J = 7.14 Hz, 1H), 5.22 (s, 1H), 
4.60–4.50 (m, 2H), 3.81–3.71 (m, 2H), 2.93 (s, 3H), 1.76–1.70 (m, 1H), 1.54 (s, 3H), 1.50 
(s, 9H), 1.34–1.30 (m, 1H), 1.25 (s, 3H), 1.23 (s, 9H), 1.07–1.02 (m, 1H).
 (1′S,2′R,3′S,4′R,5′S)-4-(6-Methylamino-9H-purin-9-yl)-1-[(di-tert-butyl 
phosphate)methyl]bicyclo[3.1.0]hexane-2,3-(O-isopropylidene) (34): 1H NMR (CDCl3) δ 
8.45 (s, 1H), 8.05 (s, 1H), 6.04 (bs, 1H), 5.30 (d, 1H, J = 7.2 Hz), 5.08 (s, 1H), 4.57 (d, 1H, J 
= 7.2 Hz), 4.47 (dd, 1H, J = 5.8, 11.0 Hz), 3.90 (dd, 1H, J = 6.3, 11.0 Hz), 3.20 (bs, 3H), 
1.79–1.71 (m, 1H), 1.54 (s, 3H), 1.51 (s, 9H), 1.50 (s, 9H), 1.29–1.26 (m, 1H), 1.22 (s, 3H), 
1.08–1.03 (m, 1H).
 (1′S,2′R,3′S,4′R,5′S)-4-(6-Methylamino-2-chloro-9H-pu-rin-9-yl)-1-[(di-tert-butyl 
phosphate)methyl]bicyclo[3.1.0]-hexane-2,3-(O-isopropylidene) (35): 1H NMR (CDCl3) 
δ 8.04 (s, 1H), 5.38 (d, 1H, J = 7.1 Hz, 1H), 5.04 (s, 1H), 4.58 (d, 1H, J = 7.1 Hz), 4.42–4.52 
(m, 1H), 3.90–4.08 (m, 1H), 3.20 (bs 3H), 1.79–1.71 (m, 1H), 1.54 (s, 3H), 1.51 (s, 9H), 
1.50 (s, 9H), 1.29–1.26 (m, 1H), 1.22 (s, 3H), 1.08–1.03 (m, 1H).
 General Procedure for Deprotection of (N)-Methanocarbaadenosine 5′-
Monophosphate Derivatives (Synthesis of 13a, 10a, 11a, 36, and 37): Deprotection was 
carried out by procedures similar to those used to prepare the unsubstituted adenine 
analogue.39
 (1′S,2′R,3′S,4′R,5′S)-4-(6-Amino-2-methylthio-9H-purin-9-yl)-1-
[phosphoryloxymethyl]bicyclo[3.1.0]hexane-2,3-diol (10a): 1H NMR (D2O) δ 8.53 (s, 
1H), 4.91 (s, 1H), 4.48 (dd, 1H, J = 4.7, 11.0 Hz), 4.05 (d, 1H, J = 6.6 Hz), 3.69 (dd, 1H, J = 
4.7, 11.0 Hz), 2.63 (s, 3H), 1.92–1.84 (m, 1H), 1.58–1.40 (m, 1H), 1.18–0.98 (m, 1H). 31P 
NMR (D2O) δ 0.613.
 (1′S,2′R,3′S,4′R,5′S)-4-(6-Amino-2-methylthiooxy-9H-purin-9-yl)-1-
[phosphoryloxymethyl]bicyclo[3.1.0]hexane-2,3-diol (11a): 1H NMR (D2O) δ 8.83 (s, 
1H), 5.46 (d, J = 6.04 Hz, 1H), 4.52 (dd, J = 4.94, 10.71 Hz, 1H), 4.06 (d, J = 6.04 Hz, 1H), 
3.72 (dd, J = 4.94, 10.71 Hz, 1H), 2.99 (s, 3H), 2.04–1.92 (m, 1H), 1.26–1.22 (m, 1H), 1.04–
0.98 (m, 1H). 31P NMR (D2O) δ 0.623.
 (1′S,2′R,3′S,4′R,5′S)-4-(6-Amino-2-chloro-9H-purin-9-yl)-1-
[phosphoryloxymethyl]bicyclo[3.1.0]hexane-2,3-di-ol (13a): 1H NMR (D2O) δ 8.60 (s, 
1H), 4.72 (s, 1H), 4.48–4.40 (m, 1H), 3.99 (d, 1H, J = 6.6 Hz), 3.62–3.76 (m, 1H), 1.94–1.82 
(m, 1H), 1.60–1.52 (m, 1H), 1.08–0.95 (m, 1H).
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The imidazolate 42, derived from 13a, displayed a single 31P NMR resonance in D2O at δ 
−11.824.
 (1′S,2′R,3′S,4′R,5′S)-4-(6-Methylamino-9H-purin-9-yl)-1-
[phosphoryloxymethyl]bicyclo[3.1.0]hexane-2,3-diol (36): 1H NMR (D2O) δ 8.47 (s, 1H), 
8.26 (s, 1H), 4.87 (s, 1H), 4.76 (d, 1H, J = 6.6 Hz), 4.46 (dd, 1H, J = 5.0, 11.0 Hz), 3.99 (d, 
1H, J = 6.6 Hz), 3.66 (dd, 1H, J = 5.0, 11.0 Hz), 3.12 (bs, 3H), 1.88–1.82 (m, 1H), 1.54–1.48 
(m, 1H), 1.00–0.92 (m, 1H).
 (1′S,2′R,3′S,4′R,5′S)-4-(6-Methylamino-2-chloro-9H-pu-rin-9-yl)-1-
[phosphoryloxymethyl]bicyclo[3.1.0]hexane-2,3-diol (37): 1H NMR (D2O) δ 8.42 (s, 1H), 
4.71 (s, 1H), 4.52 (m, 1H), 3.97 (d, 1H, J = 6.3 Hz), 3.72–3.62 (m, 1H), 3.01 (bs, 3H), 1.72–
1.80 (m, 1H), 1.62–1.48 (m, 1H), 1.04–0.94 (m, 1H).
 General Method of Synthesis of (N)-Methanocarba-ATP Analogues (8a, 12a, 14a, 
and 15a): These triphosphate derivatives were synthesized by procedures similar to the 
procedure used to prepare the unsubstituted adenine analogue39 and the procedure for 5′-
diphosphate analogue 9a.
 (1′S,2′R,3′S,4′R,5′S)-4-(6-Amino-2-methylthio-9H-purin-9-yl)-1-
[diphosphoryloxymethyl]bicyclo[3.1.0]hexane-2,3-diol (9a): A mixture of 10a (14 mg, 
0.035 mmol) and 1,1′-carbonyldiimidazole (28 mg, 0.175 mmol) in 1 mL of anhydrous 
DMF was stirred at room temperature for 6 h. Et3N/H2O/ MeOH (1:10:10 by volume, 2 mL) 
was added, and the mixture was stirred at room temperature for an additional 2 h. The 
mixture was concentrated to dryness under vacuum. To the residue, phosphoric acid (20 mg, 
0.21 mmol) was added and dried under high vacuum. This was suspended in anhydrous 
DMF (2 mL), and Et3N (0.1 mL) was added. The mixture was stirred at room temperature 
for 3 days. Triethylammonium bicarbonate (2 mL) was added, all of the solvent was 
removed under vacuum, and the residue was purified using Sephadex column 
chromatography, eluting with 150 mL of water and 150 mL of ammonium bicarbonate to 
furnish 9a (5.0 mg). 1H NMR (D2O) δ 8.34 (s, 1H), 4.87 (s, 1H), 4.71 (d, J = 6.2 Hz, 1H), 
4.54–4.48 (m, 1H), 4.02 (d, J = 6.2 Hz, 1H), 3.85–3.78 (m, 1H), 2.58 (s, 3H), 1.91–1.86 (m, 
1H), 1.54–1.46 (m, 1H), 1.02–0.96 (m, 1H). 31P NMR (D2O) δ −9.63, −10.70.
 (1′S,2′R,3′S,4′R,5′S)-4-(6-Amino-2-methylthio-9H-purin-9-yl)-1-
[triphosphoryloxymethyl]bicyclo[3.1.0]hexane-2,3-diol (8a): 1H NMR (D2O) δ 8.15 (s, 
1H), 4.10–3.98 (m, 1H), 3.90–3.74 (m, 1H), 3.67–3.61 (m, 1H), 3.57–3.52 (m, 1H), 2.59 (s, 
3H), 2.02–1.84 (m, 1H), 1.62–1.46 (m, 1H), 1.06–0.94 (m, 1H). 31P NMR (D2O) δ 0.02, 
−9.6, −10.8.
 (1′S,2′R,3′S,4′R,5′S)-4-(6-Amino-2-chloro-9H-purin-9-yl)-1-
[triphosphoryloxymethyl]bicyclo[3.1.0]hexane-2,3-diol (12a): 1H NMR (D2O) δ 8.22 (s, 
1H), 4.86 (s, 1H), 4.72 (d, 1H, J = 5.2 Hz), 3.84–3.74 (m, 2H), 2.14–2.02 (m, 1H), 1.62–1.54 
(m, 1H), 1.06–0.96 (m, 1H). 31P NMR (D2O) δ −10.55, −10.93, −22.79.
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[triphosphoryloxymethyl]bicyclo[3.1.0]hexane-2,3-di-ol (14a): 1H NMR (D2O) δ 8.44 (s, 
1H), 8.24 (s, 1H), 4.85 (d, 1H, J = 5.2 Hz), 4.75 (s, 1H), 4.57 (dd, 1H, J = 5.2, 11.3 Hz), 4.01 
(d, 1H, J = 5.2 Hz), 3.83 (dd, 1H, J = 4.7, 11.3 Hz), 3.09 (bs, 3H), 1.96–1.86 (m, 1H), 1.56–
1.48 (m, 1H), 1.04–0.96 (m, 1H). 31P NMR (D2O) δ −10.03, −10.67, −22.54.
 (1′S,2′R,3′S,4′R,5′S)-4-(6-Methylamino-2-chloro-9H-pu-rin-9-yl)-1-
[triphosphoryloxymethyl]bicyclo[3.1.0]hexane-2,3-diol (15a): 1H NMR (D2O) δ 8.42 (s, 
1H), 4.86 (s, 1H), 4.74 (s, 1H), 4.64–4.55 (m, 1H), 4.00 (s, 1H), 3.95–3.72 (m, 1H), 3.08 (bs, 
3H), 1.96–1.82 (m, 1H), 1.58–1.44 (m, 1H), 1.08–0.96 (m, 1H). 31P NMR (D2O) δ −8.05, 
−10.73, −22.19.
 (1′S,2′R,3′S,4′R,5′S)-4-(6-Amino-9H-purin-9-yl)-1-[b,g-
methylenetriphosphoryloxymethyl]bicyclo[3.1.0]hexane-2,3-diol (17a): A mixture of 
compound 7a (11 mg, 0.03 mmol)39 and 1,1′-carbonyldiimidazole (24 mg, 0.15 mmol) in 
DMF (2 mL) was stirred at room temperature for 6 h. Et3N/H2O/MeOH (1:10:10 by volume, 
1 mL) was added, and the mixture was stirred for 2 h. All of the solvent was removed under 
vacuum to dryness. The residue and methylene diphosphonic acid (0.32 g, 0.18 mmol) were 
dried under high vacuum for 1 h and suspended in anhydrous DMF (2 mL), 0.1 mL Et3N 
was added, and the mixture was stirred at room temperature for 3 days. Triethylammonium 
bicarbonate (2 mL) was added, and all of the solvent was removed under vacuum and 
purified using Sephadex column chromatography, eluting with 100 mL of water and 100 mL 
of ammonium bicarbonate to furnish 17a (4.0 mg). 1H NMR (D2O) δ 8.70 (s, 1H), 8.41 (s, 
1H), 4.98 (s, 1H), 4.59 (dd, J = 4.95, 10.72 Hz, 1H), 4.00 (d, J = 6.04 Hz, 1H), 3.82 (dd, J = 
4.95, 10.72 Hz, 1H), 2.36 (bs, 2H), 1.98–1.86 (m, 1H), 1.58–1.52 (m, 1H), 1.06–0.98 (m, 
1H). 31P NMR (D2O) δ 15.454, 9.024, −10.341.
 Phosphoric Acid Mono[(2R,3R,4S,5R)-5-(6-amino-2-chloro-9H-purin-9-yl]-3,4-
dihydroxytetrahydrofuran-2-ylmethyl]ester (13b): This monophosphate was synthesized 
by procedures similar to those used to prepare the unsubstituted adenine analogue.39 1H 
NMR (D2O) δ 8.23 (s, 1H), 5.93 (d, J = 6.04 Hz, 1H), 4.39 (s, 1H), 4.27 (s, 1H), 3.92–3.82 
(m, 2H).
 (2R,3R,4S,5R)-2-(6-Amino-2-methylsulfanyl-9H-purin-9-yl]tetrahydrofuran-3,4-(O-
isopropylidene) (47): Compound 46 (30 mg, 0.088 mmol) was dissolved in DMF (1.5 mL) 
and treated with sodium thiomethoxide (30 mg, 0.44 mmol). The reaction mixture was 
heated in a sealed tube at 90 °C for 1.5 h. The solvent was removed under vacuum, and the 
product was purified using preparative thin-layer chromatography (9/1 CHCl3/MeOH) to 
furnish 20 mg of 47 (65%). 1H NMR (CDCl3) δ 7.7 (s, 1H), 5.81 (d, J = 4.39 Hz, 1H), 5.62 
(s, 2H), 5.34–5.28 (m, 1H), 5.12 (d, J = 4.39 Hz, 1H), 4.47 (s, 1H), 3.98–3.76 (m, 2H), 2.56 
(s, 3H), 1.63 (s, 3H), 1.38 (s, 3H).
 Phosphoric Acid Mono[(2R,3R,4S,5R)-5-(6-amino-2-methylsulfanyl-9H-purin-9-
yl]-3,4-dihydroxytetrahydrofuran-2-ylmethyl]ester (10b) and Phosphoric Acid Mono-
[(2R,3R,4S,5R)-5-(6-amino-2-methylsulfinyl-9H-purin-9-yl]-3,4-
Ravi et al. Page 13














diethylphosphoramidite (0.02 mL, 0.075 mmol) was added to a mixture of 47 (18 mg, 0.05 
mmol) and tetrazole (17 mg, 0.05 mmol) in anhydrous THF (2 mL), and the mixture was 
stirred at room temperature overnight. The reaction mixture was cooled to −78 °C, treated 
with a solution of 70% mCPBA (15 mg, 0.06 mmol) in 1 mL of CH2Cl2, and warmed to 
room temperature. A total of 1 mL of MeOH was added, and the mixture was concentrated 
and purified by preparative TLC using 10% MeOH in CHCl3 to furnish 48 (10 mg) and 49 
(10 mg). These were treated with 30 mg of Dowex 50×8–200 in 1/1 H2O/MeOH at 80 °C 
for 1 h. The Dowex resin was filtered, and the filtrate was concentrated to furnish 10b (3 mg, 
15%) and 11b (3 mg, 15%).
10b: 1H NMR (D2O) δ 8.39 (s, 1H), 6.11 (d, J = 5.5 Hz, 1H), 4.82–4.95 (m, 1H), 4.45 (s, 
1H), 4.26 (s, 1H), 3.92–3.82 (m, 2H), 2.59 (s, 3H).
11b: 1H NMR (D2O) δ 8.49 (s, 1H), 6.11 (d, J = 5.5 Hz, 1H), 4.81–4.94 (m, 1H), 4.45 (s, 
1H), 4.26 (s, 1H), 3.92–3.82 (m, 2H), 2.82 (s, 3H).
 2. Enzymatic Analyses
 2.1. Hydrolysis of 5′-Triphosphate Derivatives by Recombinant Rat Ecto-5′-
nucleotidase—Catalytically active recombinant ecto-5′-nucleotidase was expressed in 
insect cells using the baculovirus system and purified as described in ref 48. Ecto-5′-
nucleotidase (0.5 μg) was incubated in Tris-buffered saline (TPS: 10 mM Tris, 150 mM 
NaCl, 0.4 mM MgCl2, pH 7.4) with the corresponding substrate (AMP, 7a, or 7c) at a final 
concentration of 100 μM. After 10 min of incubation at 37 °C, the reaction was terminated 
by addition of 5% TCA. The sample was centrifuged for 10 min at 12000g (4 °C). Inorganic 
phosphate was determined in the supernatant fraction according to the method of Lanzetta et 
al.51
 2.2. Hydrolysis of 5′-Triphosphate Derivatives by Rat NTPDase1 
(Ectoapyrase) and NTPDase2 (Ecto-ATPase) Stably Expressed in CHO Cells. 
Cell Transfection—CHO cells stably transfected with a plasmid DNA containing 
NTPDase1 (ectoapyrase) or NTPDase2 (ecto-ATPase) have previously been described.49 
They were cultured in in HAM’s FC-12 medium containing 10% fetal calf serum, 100 U/mL 
penicillin and 100 μg/mL streptomycin (Gibco BRL, Eggenstein, Germany) as described in 
ref 52.
 2.3. Measurement of Ectonucleotidase Activity—Transfected CHO cells were 
seeded in multiwell plates (20 000 cells per well, 1.88 cm2). Surface-located enzyme activity 
of intact cells was determined 24 h later at 37 °C. Cells were washed twice with 
physiological saline solution (140 mM NaCl, 5 mM KCl, 10 mM glucose, 1 mM MgCl2, 2 
mM CaCl2, 20 mM Hepes, pH 7.4) and subsequently incubated in 500 μL of the identical 
saline solution containing 50 mM of nucleotide substrate (ATP, 6a, or 6c). Aliquots of the 
culture supernatant were collected at varying time points and subjected to high-performance 
liquid chromatography (HPLC) analysis as previously described.49 The absorbance at 260 
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nm was continuously monitored, and the nucleotide and nucleoside concentrations were 
determined from the area under each absorbance peak.
 4. Pharmacological Analyses
P2Y-receptor-promoted stimulation of inositol phosphate formation was measured at human 
P2Y1, P2Y2, P2Y4, and P2Y11 receptors stably expressed in 1321N1 human astrocytoma 
cells as previously described.46,50 The K0.5 values were averaged from 3 to 8 independently 
determined concentration–effect curves for each compound. Turkey erythracytes were 
incubated in inositol-free medium (DMEM; Gibco, Gaithersburg, MD) with 0.5 mCi of 2-
[3H]myo-inositol (20 Ci/mmol; American Radiolabeled Chemicals, Inc., St. Louis, MO) for 
18–24 h in a humidified atmosphere of 95%/5% air/CO2 at 37 °C. tP2Y1 receptor-promoted 
phospholipase C activity was measured in 25 μL of [3H]inositol-labeled ghosts 
(approximately 175 μg of protein, 200–500000 cpm/assay) in a medium containing 424 μM 
CaCl2, 0.91 mM MgSO4, 2 mM EGTA, 115 mM KCl, 5 mM KH2PO4, and 10 mM Hepes, 
pH 7.0. Assays (200 μL final volume) contained 1 μM GTPγS and the indicated 
concentrations of nucleotide analogues. Membranes were incubated at 30 °C for 5 min, and 
total [3H]inositol phosphates were quantified by anion exchange chromatography as 
previously described.47,53
 5. Data Analysis
Agonist potencies were calculated using a four-parameter logistic equation and the 
GraphPad software package (GraphPad, San Diego, CA). EC50 values (mean ± standard 
error) represent the concentration at which 50% of the maximal effect is achieved. Relative 
efficacies (%) were determined by comparison with the effect produced by a maximal 
effective concentration of UTP or UDP in the same experiment.
All concentration–effect curves were repeated in at least three separate experiments, carried 
out in duplicate or triplicate using different membrane preparations.
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Effects of the (N)-methanocarba modification of 2-MeS-ATP on phospholipase C activity in 
1321N1 astrocytoma cells expressing the hP2Y1 receptor. Concentration-dependent 
stimulation of inositol phosphate formation by compounds 8a (□) and 8b (■) is shown. The 
data shown are typical curves for at least three experiments.
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Effects of the (N)-methanocarba modification of 2-MeS-ADP on phospholipase C activity in 
1321N1 astrocytoma cells expressing the hP2Y1 receptor. Concentration-dependent 
stimulation of inositol phosphate formation by compounds 9a (○) and 9b (●) is shown. The 
data shown are typical curves for at least three experiments.
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Effects of the (N)-methanocarba modification in triphosphate-modified adenine nucleotides 
on activation of phospholipase C in 1321N1 astrocytoma cells expressing hP2Y1 receptors, 
showing concentration-dependent stimulation of inositol phosphate formation by compounds 
14a (●) and 14b (○). The data shown are typical curves for at least three experiments.
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Synthesis of (N)-Methanocarbaadenosine 5′-Phosphate Derivativesa
a Reagents: (i) DEAD, Ph3P, THF; (ii) NH3 or CH3NH2, THF; (iii) palladium black, 
HCO2H, methanol; (iv) NaSCH3, DMF, 90–100 °C; (v) di-tert-butyl N,N-
diethylphosphoramidite, tetrazole, THF, room temp, 20 min and then m-CPBA, −78 °C to 
room temp; (vi) DOWEX 50×8–200, methanol, 60–70 °C, ~80%; (vii) carbonyldiimidazole, 
DMF, room temp, 6 h; (viii) 5% triethylamine/H2O/MeOH, 2 h; (ix) tributylammonium 
pyrophosphate or tributylammonium phosphate, DMF, 3 days.
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Synthesis of the (N)-Methanocarba Analogue of β,γ-Me-ATPa
a Reagents: (i) carbonyldiimidazole, DMF, room temp, 6 h; (ii) triethylamine/H2O/MeOH 
(1:10:10), 2 h; (iii) methylenediphosphonic acid, triethylamine, DMF, 3 days.
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Synthesis of Adenosine 5′-Monophosphate Analoguesa
a Reagents: (i) tetrazole, di-tert-butyl N,N-diethylphosphoramidite, THF, then m-CPBA, 
CH2Cl2; (ii) DOWEX 50W×8–200, H2O/ MeOH; (iii) NaSCH3, DMF, 90 °C.
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Table 3







Values are means of two experiments with duplicate determinations in each. The catalytic activity in the presence of AMP (100%) corresponded to 
5.6 nmol/(min μg) protein.
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Table 4
Hydrolysis of the Triphosphate Derivatives as Substrates of Rat NTPDase1 (Ectoapyrase) and NTPDase2 





6a, (N)-methanocarba-ATP39 52 4
6c, (S)-(±)-methanocarba-ATP39 57 34
a
The hydrolysis rate with the two derivatives as substrate is compared to that of ATP (100%) for each enzyme. Values are means of two 
experiments with duplicate determinations in each. Nontransfected CHO cells were analyzed as control. They contained no significant activity for 
the extracellular hydrolysis of ATP. 100% values correspond to the following: NTPDase1, 42.1 nmol/(min 106 cells); NTPDase2, 13.5 nmol/(min 
106 cells).
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